Genpact G
Genpact reports $151.66 million net income for Q3 2026
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001398659-26-000019
- Revenue of $1.39 billion for the three months ended Sep 30, 2026
- Net income of $151.66 million for the three months ended Sep 30, 2026
- Diluted EPS of $0.89 for the three months ended Sep 30, 2026
- Cash and equivalents of $499.05 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed
13 changes since the June 2026 10-Q
Compared with the 10-Q 0001398659-26-000014, filed Aug 7, 2026.
Your rights as a shareholder will change as a result of the Domestication.
Currently, your rights as a shareholder of the Company arise under Bermuda law as well as the memorandum of association and the bye-laws of the Company (the "Bermuda Memorandum" and the "Bermuda Bye-Laws," respectively).
From the filings
Now
Your rights as a shareholder will change as a result of the Domestication. Currently, your rights as a shareholder of the Company arise under Bermuda law as well as the memorandum of association and the bye-laws of the Company (the "Bermuda Memorandum" and the "Bermuda Bye-Laws," respectively). Upon effectiveness of the Domestication, your rights as a stockholder of the Company will arise under Delaware law as well as the certificate of incorporation and the bylaws of Genpact Delaware (the "Delaware Certificate" and the "Delaware Bylaws," respectively), in each case, to be effective immediately following the Domestication, in the form attached as an annex to the Domestication Proxy Statement/Prospectus. For a summary description of your rights as a stockholder of Genpact Delaware and how they differ or may differ from your rights as a shareholder of the Company as it currently exists as a company organized under the laws of Bermuda ("Genpact Bermuda"), please see the Domestication Proxy Statement/Prospectus.We expect to incur transaction costs in connection with the completion of the Domestication and related…
We expect to incur significant transaction costs in connection with the Domestication and related transactions.
From the filings
Now
We expect to incur transaction costs in connection with the completion of the Domestication and related transactions, some of which will be incurred whether or not the Domestication is completed. We expect to incur significant transaction costs in connection with the Domestication and related transactions. The substantial majority of these costs will be incurred regardless of whether the Domestication is completed and prior to the shareholder vote to approve the Domestication.The anticipated benefits of the Domestication may not be realized.
We may not realize the benefits we anticipate from the Domestication, particularly as the achievement of the benefits is in many important respects subject to factors that we do not and cannot control, including the…
From the filings
Now
The anticipated benefits of the Domestication may not be realized. We may not realize the benefits we anticipate from the Domestication, particularly as the achievement of the benefits is in many important respects subject to factors that we do not and cannot control, including the reaction of third parties with whom we enter into contracts and do business and the reaction of investors. Our failure to realize those benefits could have a material and adverse effect on our business, results of operations, cash flows or financial condition. Please see the section of the Domestication Proxy Statement/Prospectus entitled "Proposal No. 1 – Domestication Proposal—Reasons for the Domestication."The market for the Genpact Delaware common stock may differ from the market for the Genpact Bermuda common…
We expect that the Genpact Delaware common stock will trade on the New York Stock Exchange under the symbol "G," the same trading symbol as the Genpact Bermuda common shares.
From the filings
Now
The market for the Genpact Delaware common stock may differ from the market for the Genpact Bermuda common shares and the market price of Genpact Delaware common stock may as a result be subject to volatility. We expect that the Genpact Delaware common stock will trade on the New York Stock Exchange under the symbol "G," the same trading symbol as the Genpact Bermuda common shares. The market price, trading volume or volatility, or potential investor pool of the Genpact Delaware common stock may be different from those of the Genpact Bermuda common shares.We may choose to abandon or defer the Domestication at any time.
While we currently expect the Domestication to be completed effective on or around March 1, 2027, our Board may decide to defer or abandon the Domestication, at any time or for any reason, prior to the completion of…
From the filings
Now
We may choose to abandon or defer the Domestication at any time. While we currently expect the Domestication to be completed effective on or around March 1, 2027, our Board may decide to defer or abandon the Domestication, at any time or for any reason, prior to the completion of the Domestication. No assurance can be provided that the Domestication will be completed on a timely basis, or at all.Our Effective Tax Rate may change as a result of the Domestication.
Following the Domestication, Genpact Delaware will be subject to U.S. tax on its income, and the combined effective tax rate with respect to Genpact Delaware and our direct and indirect subsidiaries (the "Effective Tax…
From the filings
Now
Our Effective Tax Rate may change as a result of the Domestication. Following the Domestication, Genpact Delaware will be subject to U.S. tax on its income, and the combined effective tax rate with respect to Genpact Delaware and our direct and indirect subsidiaries (the "Effective Tax Rate") may change significantly. Any such changes to our Effective Tax Rate could materially impact our financial results, including our earnings and cash flow, and reduce the amount of cash available for dividends for periods after the Domestication. The Effective Tax Rate, which may fluctuate significantly from period to period, is based upon applicable income tax laws and regulations and judicial and administrative interpretations of these income tax laws and regulations in various jurisdictions, including many jurisdictions outside where we are organized and domiciled. The Effective Tax Rate may, however, vary significantly from the statutory rates under which we operate (including the U.S. statutory rate that would apply after the Domestication) because of, among other things, temporary differences that impact the timing in the recognition of income and expense for U.S. GAAP and tax purposes. We are unable to predict with certainty the impact of the Domestication on the Effective Tax Rate. In addition, the tax laws of the United States and other jurisdictions could change in the future, and those changes could cause a material increase in our Effective Tax Rate. The tax laws of the United States significantly limit our ability to redomicile outside of the United States once the Domestication has occurred. Accordingly, if our Effective Tax Rate were to increase as a result of the Domestication, our business and financial performance could be adversely affected.If the Domestication does not qualify as an F Reorganization, U.S. Holders of Genpact Bermuda Stock would…
As discussed more fully in the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication," it is expected that the Domestication should…
From the filings
Now
If the Domestication does not qualify as an F Reorganization, U.S. Holders of Genpact Bermuda Stock would generally recognize taxable gain or loss as a result of the Domestication. As discussed more fully in the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication," it is expected that the Domestication should constitute a reorganization within the meaning of Section 368(a)(1)(F) of the Code (an "F Reorganization"). However, your tax advisor may not agree with our intended tax treatment and the IRS may assert, or a court may sustain, a contrary position. If the Domestication does not qualify as an F Reorganization within the meaning of Section 368(a) of the Code, U.S. Holders (as defined in such section of the Domestication Proxy Statement/Prospectus) of Genpact Bermuda Stock (as defined in such section of the Domestication Proxy Statement/Prospectus) would generally recognize taxable gain or loss pursuant to the Domestication.Even if the Domestication qualifies as an F Reorganization, certain U.S. Holders of Genpact Bermuda Stock…
As noted above and discussed more fully in the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication," it is expected that the…
From the filings
Now
Even if the Domestication qualifies as an F Reorganization, certain U.S. Holders of Genpact Bermuda Stock may be required to recognize gain for U.S. federal income tax purposes as a result of the Domestication. As noted above and discussed more fully in the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication," it is expected that the Domestication should constitute an F Reorganization. Assuming that the Domestication so qualifies, U.S. Holders (as defined in such section of the Domestication Proxy Statement/Prospectus) of Genpact Bermuda Stock (as defined in such section of the Domestication Proxy Statement/Prospectus) will be subject to Section 367(b) of the Code and subject to the discussion below concerning the application of the passive foreign investment company ("PFIC") rules to the Domestication: • A U.S. Holder of Genpact Bermuda Stock whose shares have a fair market value of $50,000 or more, but who is not a 10% Shareholder (as defined in the following bullet point) will generally recognize gain (but not loss) on the deemed receipt of Genpact Stock (as defined in the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication") in the Domestication. As an alternative to recognizing gain, such U.S. Holder may file an election to include in income, as a dividend, the "all earnings and profits amount" attributable to its Genpact Bermuda Stock, provided certain other requirements are satisfied. • A U.S. Holder of Genpact Bermuda Stock who on the date of the Domestication directly, indirectly or constructively owns (i) 10% or more of the total combined voting power of all classes of Genpact Bermuda shares entitled to vote or (ii) 10% or more of the total value of all classes of Genpact Bermuda shares (a "10% Shareholder") will generally be required to include in income, as a dividend, the "all earnings and…• A U.S. Holder of Genpact Bermuda Stock whose stock has a fair market value of less than $50,000 on the…
As discussed further under the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication," Genpact Bermuda believes that it is not, and has not…
From the filings
Now
• A U.S. Holder of Genpact Bermuda Stock whose stock has a fair market value of less than $50,000 on the date of the Domestication and who is not a 10% Shareholder will not recognize any gain or loss and will not be required to include any part of Genpact Bermuda's earnings in income. As discussed further under the section of the Domestication Proxy Statement/Prospectus entitled "Material U.S. Federal Income Tax Consequences of the Domestication," Genpact Bermuda believes that it is not, and has not been, a PFIC for U.S. federal income tax purposes. In the event that Genpact Bermuda is (or, in some cases, has been) treated as a PFIC, proposed Treasury Regulations (which have a retroactive effective date), if finalized in their current form, generally would require a U.S. Holder to recognize gain as a result of the Domestication unless the U.S. Holder makes (or has made) certain elections. THE TAX CONSEQUENCES OF THE DOMESTICATION ARE COMPLEX AND WILL DEPEND ON A HOLDER'S PARTICULAR CIRCUMSTANCES. ALL HOLDERS ARE STRONGLY URGED TO CONSULT THEIR OWN TAX ADVISOR FOR A FULL DESCRIPTION AND UNDERSTANDING OF THE TAX CONSEQUENCES OF THE DOMESTICATION, INCLUDING THE APPLICABILITY AND EFFECT OF THE U.S. FEDERAL, STATE, LOCAL AND FOREIGN INCOME AND OTHER TAX LAWS. FOR A DISCUSSION OF THE MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE DOMESTICATION, SEE THE SECTION OF THE DOMESTICATION PROXY STATEMENT/PROSPECTUS ENTITLED "MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE DOMESTICATION."Net income up 4.1% from Jun 30
$152M, was $146M.
From the filings
Before
$146MNow
$152MEPS up 3.5% from Jun 30
$0.89, was $0.86.
From the filings
Before
$0.86Now
$0.89Cash down 3.5% from Jun 30
$499M, was $517M.
From the filings
Before
$517MNow
$499MRevenue up 3.1% from Jun 30
$1.4B, was $1.3B.
From the filings
Before
$1.3BNow
$1.4B
Show the redline
Section by section. Added words and removed words against the earlier filing.
Cover page 7 changes
3 unchanged paragraphs
For the Quarterly Period ended June September 30, 2026
18 unchanged paragraphs
As of August 4, November 3, 2026, there were 168,034,407 167,226,996 common shares, par value $0.01 per share, of the registrant issued and outstanding.
2 unchanged paragraphs
Consolidated Balance Sheets as of June September 30, 2026 and December 31, 2025
Consolidated Statements of Income for the three and six nine months ended J une September 30, 202 6 2026 and 2025
Consolidated Statements of Comprehensive Income (Loss) for the three and six nine months ended June September 30, 202 6 2026 and 2025
Consolidated Statements of Equity for the three and six nine months ended June September 30, 202 6 2026 and 2025
Consolidated Statements of Cash Flows for the six nine months ended June September 30, 202 6 2026 and 2025
Unaudited Consolidated Financial Statements 184 changes
3 unchanged paragraphs
Notes As of June September 30, 2026 As of December 31, 2025
Cash and cash equivalents $ 517,387 499,053 $ 853,836
1 unchanged paragraph
Accounts receivable, net of allowance for credit losses of $ 21,220 28,127 and $ 22,097 as of June September 30, 2026 and December 31, 2025, respectively
Prepaid expenses and other current assets 7 250,552 217,156 211,981
Total current assets $ 2,170,754 2,338,420 $ 2,656,367
Property, plant and equipment, net 8 184,437 188,285 190,448
Operating lease right-of-use assets 197,788 198,880 181,708
Deferred tax assets 255,068 250,831 258,789
Intangible assets, net 9 73,273 75,995 67,040
Goodwill 9 1,768,862 1,764,606 1,781,116
Contract cost assets 19 189,393 192,790 197,419
Other assets, net of allowance for credit losses of $ 13,438 17,111 and $ 10,659 as of June September 30, 2026 and December 31, 2025 (Note 4), respectively
Total assets $ 5,413,096 5,639,212 $ 5,843,267
1 unchanged paragraph
Accounts payable 16,093 27,533
Current portion of long-term debt 11 26,201 26,205 376,027
Accounts payable 24,446 27,533
Income taxes payable 51,789 53,504 43,074
Accrued expenses and other current liabilities 12 930,964 1,032,939 1,103,625
Operating lease liabilities 62,717 61,850 52,221
Total current liabilities $ 1,087,764 1,198,944 $ 1,602,480
Long-term debt, less current portion 11 1,154,056 1,147,955 1,166,274
Operating lease liabilities 154,415 153,311 150,667
Deferred tax liabilities 10,645 9,334 21,081
Other liabilities 13 401,419 421,096 353,364
Total liabilities $ 2,808,299 2,930,640 $ 3,293,866
2 unchanged paragraphs
Common shares, $ 0.01 par value, 500,000,000 authorized, 168,028,805 167,227,005 and 170,341,479 issued and outstanding as of June September 30, 2026 and December 31, 2025, respectively
Additional paid-in capital 2,050,128 2,083,374 2,018,985
Retained earnings 1,500,595 1,589,860 1,390,164
Accumulated other comprehensive income (loss) ( 947,599 966,327 ) ( 861,444 )
Total equity $ 2,604,797 2,708,572 $ 2,549,401
Commitments and contingencies 22 23
Total liabilities and equity $ 5,413,096 5,639,212 $ 5,843,267
4 unchanged paragraphs
Three months ended June 30, Six months ended June 30,
Three months ended September 30, Nine months ended September 30,
1 unchanged paragraph
Net revenues 19 $ 1,343,438 $ 1,254,418 $ 2,639,510 $ 2,469,344
Cost of revenue 853,100 804,350 1,677,504 1,590,282
Gross profit $ 490,338 $ 450,068 $ 962,006 $ 879,062
Selling, general and administrative expenses 294,129 266,393 564,466 507,477
Income from operations $ 192,942 $ 179,402 $ 391,525 $ 363,104
Foreign exchange gains, net 2,109 376 9,411 1,665
Interest income (expense), net 20 ( 15,147 ) ( 13,485 ) ( 26,749 ) ( 24,931 )
Other income (expense), net 10,979 10,445 10,690 12,123
Income before income tax expense $ 190,883 $ 176,738 $ 384,877 $ 351,961
Income tax expense 21 45,146 44,022 91,148 88,392
Net income $ 145,737 $ 132,716 $ 293,729 $ 263,569
Net revenues 19 $ 1,385,400 $ 1,291,257 $ 4,024,910 $ 3,760,601
Cost of revenue 858,683 821,601 2,536,187 2,411,883
Gross profit $ 526,717 $ 469,656 $ 1,488,723 $ 1,348,718
Selling, general and administrative expenses 312,472 262,105 876,938 769,582
Amortization of acquired intangible assets 9 3,287 4,317 6,399 8,637 8,285 9,686 16,922
Other operating (income) expense, net ( 20 ( ( 44 ) ( 384 21 ) 7,624 ( 156 405 ) 7,468
Income from operations $ 210,979 $ 191,642 $ 602,504 $ 554,746
Foreign exchange gains, net 904 3,678 10,315 5,343
Interest income (expense), net 21 ( 16,468 ) ( 12,785 ) ( 43,217 ) ( 37,716 )
Other income (expense), net 1,038 6,817 11,728 18,940
Income before income tax expense $ 196,453 $ 189,352 $ 581,330 $ 541,313
Income tax expense 22 44,796 43,521 135,944 131,913
Net income $ 151,657 $ 145,831 $ 445,386 $ 409,400
1 unchanged paragraph
Basic $ 0.86 $ 0.76 $ 1.73 $ 1.51
Diluted $ 0.86 $ 0.75 $ 1.71 $ 1.48
Basic $ 0.90 $ 0.84 $ 2.63 $ 2.35
Diluted $ 0.89 $ 0.83 $ 2.61 $ 2.31
1 unchanged paragraph
Basic 169,068,546 174,611,241 169,688,011 175,069,775
Diluted 170,425,796 177,052,346 171,635,487 177,743,745
Basic 167,920,621 173,576,957 169,098,881 174,572,169
Diluted 169,627,481 176,104,577 170,966,152 177,197,356
3 unchanged paragraphs
Three months ended June 30, Six months ended June 30,
Net income $ 145,737 $ 132,716 $ 293,729 $ 263,569
Three months ended September 30, Nine months ended September 30,
Net income $ 151,657 $ 145,831 $ 445,386 $ 409,400
1 unchanged paragraph
Currency translation adjustments ( 949 ) 34,598 ( 70,344 ) 50,011
Other comprehensive income (loss) 36,893 37,482 ( 86,155 ) 66,619
Comprehensive income $ 182,630 $ 170,198 $ 207,574 $ 330,188
Currency translation adjustments ( 21,574 ) ( 50,757 ) ( 91,918 ) ( 746 )
Gain (loss) on cash flow hedging derivatives, net of taxes (Note 6) 37,483 2,557 2,008 ( 21,416 44,140 ) 16,384 ( 19,408 ) ( 27,756 )
Retirement benefits (expense), net of taxes 359 327 5,605 224 838 ( 110 ) 6,443 114
Other comprehensive loss ( 18,728 ) ( 95,007 ) ( 104,883 ) ( 28,388 )
Comprehensive income $ 132,929 $ 50,824 $ 340,503 $ 381,012
3 unchanged paragraphs
For the three months ended June September 30, 2026
4 unchanged paragraphs
Balance as of April 1, 2026 169,504,186 $ 1,688 $ 2,021,588 $ 1,436,409 $ ( 984,492 ) $ 2,475,193
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
3 unchanged paragraphs
6 unchanged paragraphs
1 unchanged paragraph
3 unchanged paragraphs
4 unchanged paragraphs
1 unchanged paragraph
3 unchanged paragraphs
5 unchanged paragraphs
1 unchanged paragraph
3 unchanged paragraphs
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
2 unchanged paragraphs
and 104 more changes in the filing
Note 1: Organization 1 change
Genpact Limited (the "Company") is an Agentic Operations company, where applied AI meets context-rich process intelligence. The Company runs and transforms mission-critical operations for global enterprises. Its Agentic Operations are grounded in decades of operating core business processes across finance, supply chain, banking, insurance, and more. The Company has over 141,000 142,000 employees serving clients from more than 35 countries.
Note 2: Summary of significant accounting policies (Continued) 2 changes
2 unchanged paragraphs
In September 2025, the FASB issued ASU No. 2025-06, "Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40)." This ASU provides guidance to clarify and modernize the accounting for costs related to internal-use software. It removes all references to project stages in ASC Subtopic 350-40 and clarifies the threshold entities apply to begin capitalizing costs. The ASU also specifies that the property, plant and equipment disclosure requirements under ASC "Property, Plant, and Equipment (Subtopic 360-10)" apply to capitalized software costs accounted for under ASC Subtopic 350-40, regardless of how those costs are presented in the financial statements. The guidance, which applies to all entities, is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Entities may apply the guidance using a prospective, retrospective or modified transition approach. Early adoption is permitted. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.
1 unchanged paragraph
In December 2025, the FASB issued ASU No. 2025-10, "Government Grants (Topic 832)." This ASU adds guidance to ASC Topic 832 on the recognition, measurement, and presentation of government grants. In the absence of such guidance, many for-profit entities historically have analogized to other U.S. GAAP, including "Accounting for Government Grants and Disclosure of Government Assistance (IAS 20)" or ASC "Not-for-Profit Entities — Revenue Recognition — Contributions (Subtopic 958-605)," when accounting for government grants. The amendments in this ASU apply to business entities (specifically, all entities except for not-for-profit entities and employee benefit plans) that receive a government grant. The guidance under this ASU is effective for fiscal years beginning after December 15, 2028, and interim periods within those fiscal years. Early adoption is permitted. Entities may apply the guidance using a modified prospective, modified retrospective or retrospective transition approach. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.
3 unchanged paragraphs
Note 3: Business acquisitions 1 change
2 unchanged paragraphs
No portion of the purchase consideration is outstanding as of June September 30, 2026.
3 unchanged paragraphs
Note 4: Accounts receivable, net of allowance for credit losses 7 changes
1 unchanged paragraph
Six Nine months ended June September 30, 2026 Year ended December 31, 2025
1 unchanged paragraph
Closing balance $ 21,220 $ 22,097
Additions (net), charged to income statement 6,631 16,149 17,193
Deductions/effect of exchange rate fluctuations ( 7,508 10,119 ) ( 7,190 )
Closing balance $ 28,127 $ 22,097
Accounts receivable were $ 1,424,035 1,650,338 and $ 1,262,647 , and allowances for credit losses were $ 21,220 28,127 and $ 22,097 , resulting in net accounts receivable balances of $ 1,402,815 1,622,211 and $ 1,240,550 as of June September 30, 2026 and December 31, 2025, respectively.
During the three months ended September 30, 2026 and 2025, the Company recorded a charge of $ 9,518 and a release of $ 588 , respectively, and for the nine months ended September 30, 2026 and 2025, charges of $ 16,149 and $ 17,234 , respectively, to the consolidated statements of income on account of credit losses on accounts receivable.
1 unchanged paragraph
Note 4: Accounts receivable, net of allowance for credit losses (Continued) 4 changes
In addition, deferred billings were $ 297,009 362,484 and $ 232,647 and allowances for credit losses on deferred billings were $ 13,438 17,111 and $ 10,659 , resulting in net deferred billings balances of $ 283,571 345,373 and $ 221,988 as of June September 30, 2026 and December 31, 2025, respectively.
During the three months ended June September 30, 2026 and 2025, the Company recorded charges of $ 1,003 3,673 and $ 1,989 433 , respectively, and for the six nine months ended June September 30, 2026 and 2025, a charge charges of $ 2,779 6,452 and $ 541 974 , respectively, to the consolidated statements of income statement on account of credit losses on deferred billings. Deferred billings, net of related allowances for credit losses, are included under "Other assets" in the Company ' s consolidated balance sheets as of June September 30, 2026 and December 31, 2025.
The Company has a revolving accounts receivable-based facility of $ 100,000 as of June September 30, 2026 and December 31, 2025 that permits it to sell accounts receivable to banks on a non-recourse basis in the ordinary course of business. The aggregate maximum capacity utilized by the Company at any time during the six nine months ended June September 30, 2026 and year ended December 31, 2025 was $ 79,461 and $ 59,952 , respectively. The principal amount outstanding against this facility as of June September 30, 2026 and December 31, 2025 was $ 77,081 53,639 and $ 55,140 , respectively. The cost of factoring such accounts receivable during the three and six nine months ended June September 30, 2026 and 2025 was $ 726 622 and $ 403 498 , respectively, and $ 1,407 2,029 and $ 1,081 1,579 , respectively. Gains or losses on the sales are recorded at the time of transfer of the accounts receivable and are included under "interest income (expense), net" in the Company's consolidated statements of income.
The Company also has arrangements with financial institutions that manage the accounts payable program for certain of the Company's large clients. The Company sells certain accounts receivable pertaining to such clients to these financial institutions on a non-recourse basis. There is no cap on the value of accounts receivable that can be sold under these arrangements. The Company used these arrangements to sell accounts receivable amounting to $ 147,315 220,978 during the six nine months ended June September 30, 2026 and $ 327,207 during the year ended December 31, 2025, which also represent the maximum capacity utilized under these arrangements in each such period. The cost of factoring such accounts receivable during the three and six nine months ended June September 30, 2026 and 2025 was $ 1,143 1,266 and $ 1,403 1,557 , respectively, and $ 2,444 3,710 and $ 2,579 4,137 , respectively. These costs are included under "interest income (expense), net" in the Company's consolidated statements of income.
1 unchanged paragraph
Note 5: Fair value measurements 10 changes
The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these financial assets and liabilities were determined using the following inputs as of June September 30, 2026 and December 31, 2025:
As of September 30, 2026
3 unchanged paragraphs
Total $ 118,517 $ — $ 31,847 $ 86,670
Total $ 229,656 $ — $ 143,740 $ 85,916
Derivative instruments (Note a, c) $ 31,847 26,172 $ — $ 31,847 26,172 $ —
Deferred compensation plan assets (Note a, e) 86,670 86,838 — — 86,670 86,838
Total $ 113,010 $ — $ 26,172 $ 86,838
Derivative instruments (Note b, c) 143,740 131,281 — 143,740 131,281 —
Deferred compensation plan liability (Note b, f) 85,916 86,109 — — 85,916 86,109
Total $ 217,390 $ — $ 131,281 $ 86,109
12 unchanged paragraphs
Note 5: Fair value measurements (Continued) 14 changes
6 unchanged paragraphs
Three months ended June 30, Six months ended June 30,
The following table provides a roll-forward of the fair value of earn-out consideration categorized as level 3 in the fair value hierarchy for the three and six nine months ended June September 30, 2026 and 2025 :
Three months ended September 30, Nine months ended September 30,
Opening balance $ — $ — 77,500 $ 77,500 $ —
Earn-out consideration payable in connection with acquisitions — 77,500 — ( 77,500 ) 77,500
1 unchanged paragraph
Three months ended June 30, Six months ended June 30,
Opening balance $ 76,775 $ 61,812 $ 75,586 $ 61,549
Additions (net of redemption) 1,107 941 3,733 2,345
The following table provides a roll-forward of the fair value of deferred compensation plan assets categorized as level 3 in the fair value hierarchy for the three and six nine months ended June September 30, 2026 and 2025 :
Three months ended September 30, Nine months ended September 30,
Closing Opening balance $ 86,670 $ 68,356 $ 86,670 75,586 $ 68,356 61,549
Additions (net of redemption) 286 834 4,019 3,179
Change in fair value of deferred compensation plan assets (Note a) 8,788 5,603 7,351 4,462 ( 118 ) 4,089 7,233 8,551
Closing balance $ 86,838 $ 73,279 $ 86,838 $ 73,279
2 unchanged paragraphs
Note 6: Derivative financial instruments 24 changes
The Company is exposed to the risk of rate fluctuations on its foreign currency assets and liabilities and on foreign currency denominated forecasted cash flows and interest rates. The Company has established risk management policies, including the use of derivative financial instruments to hedge foreign currency assets and liabilities, foreign currency denominated forecasted cash flows and interest rate risk. These derivative financial instruments consist of deliverable and non-deliverable forward foreign exchange contracts, treasury rate locks and interest rate swaps. The Company enters into these contracts with counterparties that are banks or other financial institutions, and the Company considers the risk of non-performance by such counterparties not to be material. The forward foreign exchange contracts and interest rate swaps mature during a period of up to 42 39 months and the forecasted transactions are expected to occur during the same period.
2 unchanged paragraphs
As of June September 30, 2026 As of December 31, 2025 As of June September 30, 2026 As of December 31, 2025
1 unchanged paragraph
United States Dollars (sell) Philippines Peso (buy) 187,100 234,000 ( 8,979 ) ( 5,739 )
United States Dollars (sell) Indian Rupees (buy) $ 2,278,467 2,254,059 $ 2,771,310 $ ( 108,460 98,316 ) $ ( 72,843 )
United States Dollars (sell) Mexican Peso (buy) 50,400 39,900 71,400 4,215 2,420 2,201
United States Dollars (sell) Philippine Peso (buy) 147,150 234,000 ( 9,547 ) ( 5,739 )
Euro (sell) United States Dollars (buy) 385,648 405,668 446,846 4,705 7,945 ( 9,636 )
United States Dollars (sell) Singapore Dollar (buy) 75,000 — ( 587 ) —
Euro (sell) Romanian Leu (buy) 30,837 15,293 63,353 ( 310 113 ) 143
Japanese Yen (sell) Chinese Renminbi (buy) 62,939 57,850 67,617 7,118 5,189 3,746
United States Dollars (sell) Chinese Renminbi (buy) 61,800 51,300 82,800 1,963 2,343 144
Pound Sterling (sell) United States Dollars (buy) 68,167 56,091 92,322 492 316 ( 279 )
United States Dollars (sell) Hungarian Forint (buy) 20,000 8,000 33,000 2,279 707 2,524
Australian Dollars (sell) Indian Rupees (buy) 171,591 138,513 189,797 ( 15,003 15,433 ) ( 8,204 )
United States Dollars (sell) Polish Zloty (buy) 28,500 21,750 42,000 ( 69 667 ) 1,884
1 unchanged paragraph
United States Dollars (sell) Costa Rica Colon (buy) 27,500 44,400 2,758 773
United States Dollars (sell) Singapore Dollar (buy) 75,000 — ( 972 ) —
United States Dollars (sell) Israeli Shekel (buy) 30,000 30,000 1,467 423 1,025
South African Rand (sell) United States Dollars (buy) 15,000 18,000 ( 1,346 1,454 ) ( 1,186 )
United States Dollars (sell) Brazilian Real (buy) 4,000 4,000 244 337 ( 46 )
United States Dollars (sell) Costa Rican Colon (buy) 20,100 44,400 1,822 773
United States Dollars (sell) Canadian Dollar (buy) 9,000 9,000 ( 167 226 ) 193
United States Dollars (sell) Malaysian Ringgit (buy) 21,500 11,750 21,000 ( 64 123 ) 486
Interest rate swaps (floating to fixed) 215,625 212,500 221,875 ( 1,764 145 ) ( 4,993 )
2 unchanged paragraphs
Note 6: Derivative financial instruments (Continued) 9 changes
4 unchanged paragraphs
Other assets $ 10,124 $ 4,107 $ — $ —
Other liabilities $ 61,018 $ 44,414 $ — $ —
As of June September 30, 2026 As of December 31, 2025 As of June September 30, 2026 As of December 31, 2025
Prepaid expenses and other current assets $ 15,068 12,692 $ 9,257 $ 6,655 4,830 $ 2,076
Other assets $ 8,645 $ 4,107 $ 5 $ —
Accrued expenses and other current liabilities $ 71,501 68,669 $ 47,648 $ 11,221 6,154 $ 12,947
Other liabilities $ 56,458 $ 44,414 $ — $ —
1 unchanged paragraph
In March 2021, the Company executed a treasury rate lock agreement for $ 350,000 in connection with future interest payments to be made on its senior notes issued in March 2021 by Genpact Luxembourg S.à r.l. ("Genpact Luxembourg") and Genpact USA, Inc. ("Genpact USA"), both wholly-owned subsidiaries of the Company, and the treasury rate lock was designated as a cash flow hedge. The treasury rate lock agreement was terminated on March 23, 2021 and a deferred gain was recorded in accumulated other comprehensive income (loss). This gain is being amortized to interest expense over the life of the 2021 Senior Notes (as defined in Note 11 below). The remaining gain to be amortized related to the treasury rate lock agreement as of June September 30, 2026 and December 31, 2025 was $ 0 and $ 44 , respectively. The 2021 Senior Notes were repaid on April 10, 2026.
In May 2024, the Company executed treasury rate lock agreements for $ 400,000 in connection with future interest payments to be made on its senior notes issued in June 2024 by Genpact Luxembourg and Genpact USA, and the treasury rate locks were designated as cash flow hedges. These treasury rate lock agreements were terminated on May 30, 2024 and a deferred loss was recorded in accumulated other comprehensive income (loss). This loss is being amortized to interest expense over the life of the 2024 Senior Notes (as defined in Note 11 below). The remaining loss to be amortized related to the treasury rate lock agreements as of June September 30, 2026 and December 31, 2025 was $ 232 212 and $ 272 , respectively.
1 unchanged paragraph
Note 7: Prepaid expenses and other current assets 14 changes
1 unchanged paragraph
Prepaid expenses 54,788 51,778
Employee advances 4,188 3,353
Others 59,761 43,676
Total $ 250,552 $ 211,981
As of June September 30, 2026 As of December 31, 2025
Advance income and non-income taxes $ 60,973 60,418 $ 61,065
Contract asset (Note 19) 43,644 50,820 35,583
Prepaid expenses 60,470 51,778
Derivative instruments (Note 6) 21,723 17,522 11,333
Employee advances 2,895 3,353
Deposits 3,313 3,691 2,280
Advances to suppliers 2,162 3,935 2,913
Others 17,405 43,676
Total $ 217,156 $ 211,981
Note 8: Property, plant and equipment, net 5 changes
1 unchanged paragraph
As of June September 30, 2026 As of December 31, 2025
Property, plant and equipment, gross* $ 755,330 760,932 $ 773,392
Less: Accumulated depreciation and amortization ( 570,893 572,647 ) ( 582,944 )
Property, plant and equipment, net $ 184,437 188,285 $ 190,448
1 unchanged paragraph
Depreciation expense on property, plant and equipment for the three months ended June 30, 2026 and 2025 was $ 12,625 and $ 13,515 , respectively, and for the six months ended June 30, 2026 and 2025 was $ 26,000 and $ 26,992 , respectively. Computer software amortization for the three months ended June 30, 2026 and 2025 was $ 269 and $ 573 , respectively, and for the six months ended June 30, 2026 and 2025 was $ 630 and $ 1,075 , respectively.
1 unchanged paragraph
Note 9: Goodwill and intangible assets 19 changes
The following table presents the changes in goodwill for the six nine months ended June September 30, 2026 and year ended December 31, 2025:
For the six Nine months ended June September 30, 2026 For the year ended December 31, 2025
3 unchanged paragraphs
Effect of exchange rate fluctuations ( 12,254 16,510 ) ( 924 )
Closing balance $ 1,768,862 1,764,606 $ 1,781,116
The following table presents the changes in goodwill by reporting unit for the six nine months ended June September 30, 2026:
2 unchanged paragraphs
Effect of exchange rate fluctuations ( 2,781 ) ( 4,585 ) ( 4,888 ) ( 12,254 )
Closing balance $ 408,647 $ 671,899 $ 688,316 $ 1,768,862
Effect of exchange rate fluctuations ( 3,790 ) ( 6,203 ) ( 6,517 ) ( 16,510 )
Closing balance $ 407,638 $ 670,281 $ 686,687 $ 1,764,606
7 unchanged paragraphs
The Company's intangible assets are as follows:
As of June 30, 2026 As of December 31, 2025
carrying amount Accumulated amortization
& Impairment Net Gross
carrying amount Accumulated amortization
Customer-related intangible assets $ 510,856 $ 462,760 $ 48,096 $ 513,977 $ 459,682 $ 54,295
Marketing-related intangible assets 102,153 102,153 — 102,233 102,208 25
Technology-related intangible assets 158,807 133,630 25,177 141,659 128,939 12,720
Amortization expenses for intangible assets acquired as part of a business combination and disclosed in the consolidated statements of income under amortization of acquired intangible assets for the three months ended June 30, 2026 and 2025 were $ 3,287 and $ 4,317 , respectively, and for the six months ended June 30, 2026 and 2025 were $ 6,399 and $ 8,637 , respectively.
The total amount of the Company's goodwill deductible for income tax purposes was $ 196,284 189,151 and $ 210,585 as of June September 30, 2026 and December 31, 2025, respectively.
1 unchanged paragraph
Note 9: Goodwill and intangible assets (Continued) 10 changes
The Company's intangible assets are as follows:
As of September 30, 2026 As of December 31, 2025
carrying amount Accumulated amortization
& Impairment Net Gross
carrying amount Accumulated amortization
Customer-related intangible assets $ 510,092 $ 465,107 $ 44,984 $ 513,977 $ 459,682 $ 54,295
Marketing-related intangible assets 102,028 102,028 — 102,233 102,208 25
Technology-related intangible assets 167,023 136,012 31,011 141,659 128,939 12,720
Amortization expenses for intangible assets acquired as part of a business combination and disclosed in the consolidated statements of income under amortization of acquired intangible assets for the three months ended September 30, 2026 and 2025 were $ 3,287 and $ 8,285 , respectively, and for the nine months ended September 30, 2026 and 2025 were $ 9,686 and $ 16,922 , respectively.
Amortization expenses for internally-developed internally developed and other intangible assets disclosed in the consolidated statements of income under cost of revenue and selling, general and administrative expenses for the three months ended June September 30, 2026 and 2025 were $ 2,286 2,530 and $ 700 920 , respectively, and for the six nine months ended June September 30, 2026 and 2025 were $ 4,070 6,600 and $ 1,318 2,238 , respectively.
Note 10: Short-term borrowings 2 changes
1 unchanged paragraph
a. Fund-based and non-fund-based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of June September 30, 2026 and December 31, 2025, the limits available were $ 30,920 30,599 and $ 26,563 , respectively, of which $ 7,644 7,848 and $ 7,988 , respectively, was utilized, constituting non-funded drawdown.
b. A fund-based and non-fund based revolving credit facility of $ 650,000 , which the Company obtained by entering into an amended and restated credit agreement (the "2022 Credit Agreement") with Genpact USA, Genpact Global Holdings (Bermuda) Limited ("GGH") and Genpact Luxembourg, each wholly owned subsidiaries a wholly-owned subsidiary of the Company (Genpact Luxembourg, Genpact USA and GGH, collectively, the "Borrowers"), as borrowers, Wells Fargo, National Association ("Wells Fargo"), as administrative agent, swingline lender and issuing bank, and the lenders and other parties thereto on December 13, 2022. The term loan and revolving credit facility under the 2022 Credit Agreement expire on December 13, 2027. Borrowings under the 2022 Credit Agreement bear interest at a rate equal to, at the election of the Company, either Adjusted Term SOFR (which is the rate per annum equal to (a) Term SOFR (the forward-looking secured overnight financing rate) plus (b) a Term SOFR Adjustment of 0.10 % per annum, but in no case lower than 0.0 %) plus an applicable margin equal to 1.375 % per annum or a base rate plus an applicable margin equal to 0.375 % per annum. The unutilized amount on the revolving credit facility under the 2022 Credit Agreement bore a commitment fee of 0.20 % as of June September 30, 2026 and December 31, 2025. As of June September 30, 2026 and December 31, 2025, a total of $ 1,257 was utilized, all of which constituted non-funded drawdown. The 2022 Credit Agreement contains certain customary covenants, including a maximum leverage covenant and a minimum interest coverage ratio. As of June September 30, 2026 and December 31, 2025, the Company was in compliance with the financial covenants of the 2022 Credit Agreement.
Note 11: Long-term debt 3 changes
Borrowings under the 2022 Credit Agreement bear interest at a rate equal to, at the election of the Company, either Adjusted Term SOFR (which is the rate per annum equal to (a) Term SOFR (the forward-looking secured overnight financing rate) plus (b) a Term SOFR Adjustment of 0.10 % per annum, but in no case lower than 0.00 %) plus an applicable margin equal to 1.375 % per annum or a base rate plus an applicable margin equal to 0.375 % per annum, in each case subject to adjustment based on the Borrowers' debt ratings provided by Standard & Poor's Rating Services and Moody's Investors Service, Inc. (the "Debt Ratings"). The revolving credit commitments under the 2022 Credit Agreement are subject to a commitment fee equal to 0.20 % per annum, subject to adjustment based on the Debt Ratings. The commitment fee accrues on the actual daily amount by which the aggregate revolving commitments exceed the sum of outstanding revolving loans and letter of credit obligations.
The 2022 Credit Agreement restricts certain payments, including dividend payments, if there is an event of default under the 2022 Credit Agreement or if the Company is not, or after making the payment would not be, in compliance with certain financial covenants contained in the 2022 Credit Agreement. These covenants require the Company to maintain a net debt to EBITDA leverage ratio of less than 3 x and an interest coverage ratio of more than 3 x. As of June 30, 2026, the Company was in compliance with the terms of the 2022 Credit Agreement, including all of the financial covenants therein. The Company's retained earnings are not subject to any restrictions on availability to make dividend payments to shareholders, subject to compliance with the financial covenants described above that are contained in the 2022 Credit Agreement.
In December 2022, the Company amended its existing credit facility under its amended and restated credit agreement entered into in August 2018 and entered into the 2022 Credit Agreement, which is comprised of a $ 530,000 term loan and a $ 650,000 revolving credit facility, described in Note 10. The 2022 Credit Agreement is guaranteed by the Company and certain of its subsidiaries. The obligations under the 2022 Credit Agreement are unsecured.
1 unchanged paragraph
Note 11: Long-term debt (Continued) 9 changes
The Company paid interest on the 2021 Senior Notes semi-annually in arrears on April 10 and October 10 of each year through the maturity date of April 10, 2026. The Company pays interest on (i) the 2024 Senior Notes semi-annually in arrears on June 4 and December 4 of each year and (ii) the 2025 Senior Notes semi-annually in arrears on May 18 and November 18 of each year, ending on the maturity dates of June 4, 2029 and November 18, 2030, respectively. The Company, at its option, may redeem the Senior Notes at any time in whole or in part, at a redemption price equal to (i) 100 % of the principal amount of the notes redeemed, together with accrued and unpaid interest on the redeemed amount, and (ii) if the notes are redeemed prior to, in the case of the 2024 Senior Notes, May 4, 2029, and in the case of the 2025 Senior Notes, October 18, 2030, a specified "make-whole" premium. Additionally, the Company may redeem any series of Senior Notes in whole, but not in part, at any time at a redemption price equal to 100 % of the principal amount thereof, together with accrued and unpaid interest to the redemption date, in the event of certain changes in taxation in any jurisdiction (other than the U.S.) having authority to tax the issuers. Upon certain change of control transactions, the applicable issuer or issuers will be required to make an offer to repurchase the Senior Notes at a price equal to 101 % of the aggregate principal amount of the Senior Notes, plus accrued and unpaid interest. The Senior Notes are subject to certain customary covenants, including limitations on the ability of the Company and certain of its subsidiaries to incur debt secured by liens, engage in certain sale and leaseback transactions and consolidate, merge, convey or transfer their assets substantially as an entirety. During the period ended June 30, 2026, the Company and its applicable subsidiaries were in compliance with the covenants under the Senior Notes.
Borrowings under the 2022 Credit Agreement bear interest at a rate equal to, at the election of the Company, either Adjusted Term SOFR (which is the rate per annum equal to (a) Term SOFR (the forward-looking secured overnight financing rate) plus (b) a Term SOFR Adjustment of 0.10 % per annum, but in no case lower than 0.00 %) plus an applicable margin equal to 1.375 % per annum or a base rate plus an applicable margin equal to 0.375 % per annum, in each case subject to adjustment based on the Borrowers' debt ratings provided by Standard & Poor's Rating Services and Moody's Investors Service, Inc. (the "Debt Ratings"). The revolving credit commitments under the 2022 Credit Agreement are subject to a commitment fee equal to 0.20 % per annum, subject to adjustment based on the Debt Ratings. The commitment fee accrues on the actual daily amount by which the aggregate revolving commitments exceed the sum of outstanding revolving loans and letter of credit obligations.
The 2022 Credit Agreement restricts certain payments, including dividend payments, if there is an event of default under the 2022 Credit Agreement or if the Company is not, or after making the payment would not be, in compliance with the covenants contained in the 2022 Credit Agreement. These covenants require the Company to maintain a net debt to EBITDA leverage ratio of less than 3 x and an interest coverage ratio of more than 3 x. As of September 30, 2026, the Company was in compliance with the terms of the 2022 Credit Agreement, including the covenants therein. The Company's retained earnings are not subject to any restrictions on availability to make dividend payments to shareholders, subject to compliance with the covenants described above that are contained in the 2022 Credit Agreement.
As of June September 30, 2026 and December 31, 2025, the amount outstanding under the Company's term loan, net of unamortized debt issuance costs of $ 429 352 and $ 584 , was $ 436,821 430,273 and $ 449,916 , respectively.
Indebtedness under the 2022 Credit Agreement is unsecured. The amount outstanding on the term loan as of June September 30, 2026 requires quarterly payments of $ 6,625 , and the balance of the loan is due and payable upon the maturity of the term loan on December 13, 2027.
The maturity profile of the term loan outstanding as of June September 30, 2026, net of unamortized debt issuance costs, is as follows:
In March 2021, Genpact Luxembourg and Genpact USA co-issued $ 350,000 aggregate principal amount of 1.750 % senior notes (the "2021 Senior Notes"). The 2021 Senior Notes were fully guaranteed by the Company and Genpact UK Finco plc. The total debt issuance cost of $ 3,032 incurred in connection with the 2021 Senior Notes was amortized over the life of the 2021 Senior Notes as additional interest expense. As of June September 30, 2026 and December 31, 2025, the amount outstanding under the 2021 Senior Notes, net of unamortized debt issuance costs of $ 0 and $ 165 , respectively, was $ 0 and $ 349,835 , respectively. The 2021 Senior Notes were repaid on April 10, 2026.
In June 2024, Genpact Luxembourg and Genpact USA co-issued $ 400,000 aggregate principal amount of 6.000 % senior notes (the "2024 Senior Notes"). The 2024 Senior Notes are fully guaranteed by the Company and Genpact UK Finco plc. The total debt issuance cost of $ 4,395 incurred in connection with the 2024 Senior Notes is being amortized over the life of the 2024 Senior Notes as additional interest expense. As of June September 30, 2026 and December 31, 2025, the amount outstanding under the 2024 Senior Notes, net of unamortized debt issuance costs of $ 2,571 2,350 and $ 3,005 , respectively, was $ 397,429 397,650 and $ 396,994 , respectively, which is payable on June 4, 2029.
In November 2025, Genpact UK Finco plc and Genpact USA co-issued $ 350,000 aggregate principal amount of 4.950 % senior notes (the "2025 Senior Notes," and together with the 2024 Senior Notes, the "Senior Notes"). The 2025 Senior Notes are fully guaranteed by the Company and Genpact Luxembourg. The total debt issuance cost of $ 4,551 incurred in connection with the 2025 Senior Notes is being amortized over the life of the 2025 Senior Notes as additional interest expense. As of June September 30, 2026 and December 31, 2025, the amount outstanding under the 2025 Senior Notes, net of unamortized debt issuance costs of $ 3,993 3,763 and $ 4,444 , respectively, was $ 346,007 346,237 and $ 345,556 , respectively, which is payable on November 18, 2030.
1 unchanged paragraph
Note 12: Accrued expenses and other current liabilities 16 changes
1 unchanged paragraph
Accrued expenses $ 299,235 $ 221,316
Statutory liabilities 71,937 88,847
Compensated absences 34,587 30,414
As of June September 30, 2026 As of December 31, 2025
Accrued expenses $ 268,619 $ 221,316
Accrued employee cost 246,072 323,073 380,914
Statutory liabilities 80,360 88,847
Retirement benefits 1,800 1,864 2,334
Compensated absences 35,256 30,414
Derivative instruments (Note 6) 82,722 74,823 60,595
Contract liabilities (Note 19) 152,588 197,293 203,128
Finance lease liabilities 8,658 7,400 9,444
1 unchanged paragraph
Other liabilities 26,223 25,302
Deferred compensation plan liability (Note 5) 7,142 7,046 3,831
Other liabilities 37,205 25,302
GENPACT LIMITED AND ITS SUBSIDIARIES
Note 13: Other liabilities 13 changes
1 unchanged paragraph
Accrued expenses $ 124,105 $ 100,573
Retirement benefits 18,844 17,237
Compensated absences 53,941 51,780
GENPACT LIMITED AND ITS SUBSIDIARIES
As of June September 30, 2026 As of December 31, 2025
Accrued expenses $ 137,390 $ 100,573
Accrued employee cost 5,578 7,583 4,406
Retirement benefits 19,007 17,237
Compensated absences 55,869 51,780
Derivative instruments (Note 6) 61,018 56,458 44,414
Contract liabilities (Note 19) 45,248 51,580 47,063
Finance lease liabilities 8,569 8,055 9,864
Deferred compensation plan liability (Note 5) 78,774 79,063 70,989
Note 14: Employee benefit plans 21 changes
5 unchanged paragraphs
Three months ended June 30, Six months ended June 30,
Service costs $ 6,036 $ 4,659 $ 12,148 $ 9,551
Interest costs 2,683 2,194 5,452 4,353
Amortization of actuarial loss 95 77 190 151
Expected return on plan assets ( 2,075 ) ( 1,743 ) ( 4,266 ) ( 3,450 )
Net defined benefit plan costs $ 7,487 $ 5,187 $ 14,883 $ 10,605
Defined contribution plans
During the three and six months ended June 30, 2026 and 2025, the Company contributed the following amounts to defined contribution plans in various jurisdictions:
Three months ended June 30, Six months ended June 30,
India $ 15,197 $ 15,534 $ 30,321 $ 29,876
China 7,616 7,372 15,104 14,770
Other regions 4,678 4,859 9,659 9,952
Total $ 34,844 $ 36,830 $ 75,585 $ 73,764
Net defined benefit plan costs for the three and six nine months ended June September 30, 2026 and 2025 include the following components:
Three months ended September 30, Nine months ended September 30,
Service costs $ 5,977 $ 4,657 $ 18,125 $ 14,208
Interest costs 2,665 2,170 8,117 6,523
Amortization of actuarial loss 93 76 283 227
Amortization of prior service cost 748 738 — 1,359 2,097 —
Expected return on plan assets ( 2,064 ) ( 1,710 ) ( 6,330 ) ( 5,160 )
Net defined benefit plan costs $ 7,409 $ 5,193 $ 22,292 $ 15,798
1 unchanged paragraph
Note 14: Employee benefit plans (Continued) 11 changes
Defined contribution plans
During the three and nine months ended September 30, 2026 and 2025, the Company contributed the following amounts to defined contribution plans in various jurisdictions:
Three months ended September 30, Nine months ended September 30,
India $ 15,081 $ 15,623 $ 45,402 $ 45,499
China 7,579 7,221 22,683 21,991
Other regions 7,254 5,746 16,913 15,698
Total $ 39,468 $ 38,861 $ 115,053 $ 112,625
4 unchanged paragraphs
During the three months ended June 30, 2026 and 2025, the change in the fair value of deferred compensation plan assets was $ 8,788 and $ 5,603 , respectively, and during the six months ended June 30, 2026 and 2025, the change in the fair value of deferred compensation plan assets was $ 7,351 and $ 4,462 , respectively, which is included in "other income (expense), net," in the consolidated statements of income. During the three months ended June 30, 2026 and 2025, the change in the fair value of deferred compensation plan liabilities was $ 8,776 and $ 5,595 , respectively, and during the six months ended June 30, 2026 and 2025, the change in the fair value of deferred compensation plan liabilities was $ 7,348 and $ 4,463 , respectively, which is included in "selling, general and administrative expenses."
The liability for the Plan was $ 85,916 86,109 and $ 74,820 as of June September 30, 2026 and December 31, 2025, respectively, and is included in "accrued expenses and other current liabilities" and "other liabilities" in the consolidated balance sheets.
In connection with the administration of the Plan, the Company has purchased Company-owned life insurance policies insuring the lives of certain employees. The cash surrender value of these policies was $ 86,670 86,838 and $ 75,586 as of June September 30, 2026 and December 31, 2025, respectively. The cash surrender value of these insurance policies is included in "other assets" in the consolidated balance sheets.
GENPACT LIMITED AND ITS SUBSIDIARIES
Note 15: Stoc k-based compensation 5 changes
3 unchanged paragraphs
On May 9, 2017, the Company's shareholders approved the adoption of the 2017 Omnibus Plan, pursuant to which 15,000,000 Company common shares are available for issuance. The 2017 Omnibus Plan was amended and restated on April 5, 2019 and April 5, 2022 to increase the number of common shares authorized for issuance by 8,000,000 shares to 23,000,000 shares and by 3,500,000 shares to 26,500,000 shares, respectively. No grants may be made under the 2007 Omnibus Plan after the date of adoption of the 2017 Omnibus Plan. Grants that were outstanding under the 2007 Omnibus Plan as of the date of the Company's adoption of the 2017 Omnibus Plan remain subject to the terms of the 2007 Omnibus Plan.
Stock-based compensation costs relating to the foregoing plans during the three months ended September 30, 2026 and 2025 were $ 31,068 and $ 21,994 , respectively, and for the nine months ended September 30, 2026 and 2025 were $ 78,999 and $ 63,335 , respectively, and have been allocated to "cost of revenue" and "selling, general and administrative expenses."
All options granted under the 2007 Omnibus Plan and 2017 Omnibus Plan are exercisable into common shares of the Company, have a contractual period of ten years and vest over three to five years unless specified otherwise in the applicable award agreement. The Company recognizes compensation cost over the vesting period of the option.
Compensation cost is determined at the date of grant by estimating the fair value of an option using the Black-Scholes option-pricing model.
No options were granted in the nine months ended September 30, 2026 and 2025.
1 unchanged paragraph
Note 15: Stoc k-based compensation (Continued) 21 changes
Six months ended June 30, 2026
Number of Restricted Share Units Weighted Average Grant Date Fair Value
Outstanding as of January 1, 2026 2,302,336 $ 42.29
Granted 1,390,989 43.69
Vested (Note a) ( 926,732 ) 40.69
Forfeited ( 170,716 ) 44.27
Outstanding as of June 30, 2026 2,595,877 43.48
Expected to vest (Note b) 2,348,090
(a) 922,834 RSUs vested during the six months ended June 30, 2026, in respect of which 578,258 shares (net of minimum statutory tax withholding) were issued. 3,898 RSUs that vested in the six months ended June 30, 2026 will be issued subsequent to June 30, 2026 after withholding shares to the extent of minimum statutory withholding taxes.
(b) The number of RSUs expected to vest reflects the application of an estimated forfeiture rate.
64,195 RSUs vested in the year ended December 31, 2024, in respect of which 64,175 shares were issued during the six months ended June 30, 2026 after withholding shares to the extent of minimum statutory withholding taxes.
In addition, 50,536 shares underlying RSUs that vested in the year ended December 31, 2025 will be issued at the end of 2026 after withholding shares to the extent of minimum statutory withholding taxes.
As of June September 30, 2026, the total remaining unrecognized stock-based compensation cost related to RSUs amounted to $ 79,061 68,048 , which will be recognized over the weighted average remaining requisite vesting period of 2.1 1.9 years.
7 unchanged paragraphs
• For determining the TSR of the Company and the companies in the Peer Group, dividends are assumed to have been reinvested in the stock of the issuing entities on a continuous basis.
• The correlation coefficients used to model the way in which each entity tends to move in relation to each other are based upon the price data used to calculate historical volatility.
The fair value of each PU granted to employees in the nine months ended September 30, 2026 and 2025 was estimated on the date of grant using the following valuation assumptions:
Nine months ended September 30, 2026 Nine months ended September 30, 2025
Dividend yield 1.54 % 1.37 %
Expected life (years) 2.92 2.81
Risk-free rate of interest for expected life 3.56 % 3.89 %
Volatility for expected life 28.86 % 25.78 %
1 unchanged paragraph
Note 16: Capital stock 7 changes
During the six months ended June 30, 2026 and 2025, the Company repurchased 3,372,227 and 1,898,010 of its common shares, respectively, on the open market at a weighted average price of $ 35.57 and $ 48.98 per share, respectively, for an aggregate cash amount of $ 119,940 and $ 92,961 , respectively. All repurchased shares have been retired.
The Company records repurchases of its common shares on the settlement date of each transaction. Shares purchased and retired are deducted to the extent of their par value from common shares and from retained earnings for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares purchased. For the six months ended June 30, 2026 and 2025, retained earnings were reduced by the direct costs, including taxes, related to share repurchases of $ 67 and $ 538 , respectively.
$ 244,137 remained available for share repurchases under the Company's existing share repurchase program as of June 30, 2026. This repurchase program does not obligate the Company to acquire any specific number of shares and does not specify an expiration date.
On February 5, 2026, the Company announced that its Board approved a 10 % increase in its quarterly cash dividend to $ 0.1875 per share for 2026, up from $ 0.17 per share in 2025, representing a planned annual dividend of $ 0.75 per common share for 2026, up from $ 0.68 per share in 2025, payable to holders of the Company's common shares. On March 31, 2026 and June 25, 2026, the Company paid a dividend of $ 0.1875 per share, amounting to $ 31,773 and $ 31,552 in the aggregate, to shareholders of record as of March 16, 2026 and June 10, 2026, respectively.
On February 6, 2025, the Company announced that its Board had approved an 11 % increase in its quarterly cash dividend to $ 0.17 per share for 2025, up from $ 0.1525 per share in 2024, representing an annual dividend of $ 0.68 per common share for 2025, up from $ 0.61 per share in 2024, payable to holders of the Company's common shares. On March 26, 2025 and June 30, 2025, the Company paid a dividend of $ 0.17 per share, amounting to $ 29,784 and $ 29,624 in the aggregate, to shareholders of record as of March 11, 2025 and June 18, 2025, respectively.
The Board of Directors of the Company (the "Board") has authorized repurchases of up to $ 2,750,000 under the Company's existing share repurchase program of up to $ 2,750,000 , of which $ 213,193 remained available as of September 30, 2026. Under the program, shares may be purchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. This repurchase program does not obligate the Company to acquire any specific number of shares and does not specify an expiration date.
GENPACT LIMITED AND ITS SUBSIDIARIES
Note 17: Earnings per share 1 change
1 unchanged paragraph
The number of shares subject to stock awards outstanding but not included in the computation of diluted earnings per common share because their effect was anti-dilutive is 3,254,815 and 952,901 for the nine months ended September 30, 2026 and 2025, respectively, and 3,389,783 and 1,121,406 for the three months ended September 30, 2026 and 2025, respectively.
1 unchanged paragraph
Note 17: Earnings per share (Continued) 13 changes
The number of shares subject to stock awards outstanding but not included in the computation of diluted earnings per common share because their effect was anti-dilutive is 3,845,295 and 868,648 for the six months ended June 30, 2026 and 2025, respectively, and 4,499,624 and 1,121,406 for the three months ended June 30, 2026 and 2025, respectively.
Three months ended June 30, Six months ended June 30,
Net income $ 145,737 $ 132,716 $ 293,729 $ 263,569
Dilutive effect of stock-based awards 1,357,250 2,441,105 1,947,476 2,673,970
Three months ended September 30, Nine months ended September 30,
Net income $ 151,657 $ 145,831 $ 445,386 $ 409,400
Weighted average number of common shares used in computing basic earnings per common share 169,068,546 174,611,241 169,688,011 175,069,775 167,920,621 173,576,957 169,098,881 174,572,169
Dilutive effect of stock-based awards 1,706,860 2,527,620 1,867,271 2,625,187
Weighted average number of common shares used in computing dilutive earnings per common share 170,425,796 177,052,346 171,635,487 177,743,745 169,627,481 176,104,577 170,966,152 177,197,356
1 unchanged paragraph
Basic $ 0.86 $ 0.76 $ 1.73 $ 1.51
Diluted $ 0.86 $ 0.75 $ 1.71 $ 1.48
Basic $ 0.90 $ 0.84 $ 2.63 $ 2.35
Diluted $ 0.89 $ 0.83 $ 2.61 $ 2.31
Note 18: Segment reporting (Continued) 36 changes
Net r evenues, revenues, cost of revenue, other segment items and AOI for each of the Company's segments for the six nine months ended June September 30, 2026 were as follows:
1 unchanged paragraph
Financial Services $ 694,928 $ 423,364 $ 137,474 $ 134,090
Consumer and Healthcare 915,483 606,049 172,198 137,236
High Tech and Manufacturing 1,029,099 648,091 198,859 182,149
Net revenues $ 2,639,510
Unallocated corporate expenses ( 3,761 ) 3,761
Net income $ 293,729
Financial Services $ 1,063,053 $ 642,928 $ 206,117 $ 214,008
Consumer and Healthcare 1,391,150 909,285 256,942 224,923
High Tech and Manufacturing 1,570,707 983,974 294,874 291,859
Total $ 4,024,910 $ 2,536,187
Unallocated corporate expenses 27,019 ( 27,019 )
Stock-based compensation ( 48,632 79,863 )
Amortization of acquired intangible assets ( 6,389 9,676 )
Foreign exchange gains, net 9,411 10,315
Interest income (expense), net ( 26,749 43,217 )
Income tax expense ( 91,148 135,944 )
Net income $ 445,386
1 unchanged paragraph
Net r evenues, revenues, cost of revenue, other segment items and AOI for each of the Company's segments for the six nine months ended June September 30, 2025 were as follows:
1 unchanged paragraph
Financial Services $ 665,837 $ 420,629 $ 123,559 $ 121,649
Consumer and Healthcare 849,049 552,445 150,249 146,355
High Tech and Manufacturing 954,458 617,208 167,119 170,131
Net revenues $ 2,469,344
Unallocated corporate expenses 11,131 ( 11,131 )
Financial Services $ 1,008,630 $ 636,036 $ 186,968 $ 185,626
Consumer and Healthcare 1,278,854 831,281 229,005 218,568
High Tech and Manufacturing 1,473,117 944,566 257,243 271,308
Total $ 3,760,601 $ 2,411,883
Unallocated corporate expenses 19,591 ( 19,591 )
Stock-based compensation ( 41,834 64,055 )
Amortization of acquired intangible assets ( 8,633 16,860 )
Foreign exchange gains, net 1,665 5,343
Interest income (expense), net ( 24,931 37,716 )
1 unchanged paragraph
Net income $ 263,569
Income tax expense ( 88,392 131,913 )
Net income $ 409,400
2 unchanged paragraphs
Note 19: Net revenues 9 changes
1 unchanged paragraph
Effective January 1, 2026, the Company revised its revenue disaggregation to better align with its current business structure, strategic priorities and internal reporting. The Company's revenue is now disaggregated between Advanced Technology Solutions and Core Business Services, replacing the prior disaggregation between Data-Tech-AI and Digital Operations. Accordingly, no disaggregation of revenue between Data-Tech-AI and Digital Operations has been presented for the three and six nine months ended June September 30, 2026 and June September 30, 2025.
3 unchanged paragraphs
Three months ended June 30, Six months ended June 30,
Three months ended September 30, Nine months ended September 30,
2 unchanged paragraphs
Net revenues $ 1,343,438 $ 1,254,418 $ 2,639,510 $ 2,469,344
Net revenues $ 1,385,400 $ 1,291,257 $ 4,024,910 $ 3,760,601
4 unchanged paragraphs
As of June September 30, 2026 As of December 31, 2025
Contract assets (Note a) $ 75,167 81,202 $ 64,811
1 unchanged paragraph
Deferred transition revenue $ 88,207 94,137 $ 90,607
Advance from customers $ 109,629 154,736 $ 159,584
3 unchanged paragraphs
Note 19: Net revenues (Continued) 13 changes
Changes in the Company's contract asset and liability balances during the three and six nine months ended September 30, 2026 and 2025 were a result of normal business activity and were not materially impacted by any other factors.
The amount of revenue recognized during the three months ended June September 30, 2026 and 2025 that was included in the Company's contract liabilities balance at the beginning of each period was $ 100,835 87,301 and $ 47,059 51,149 , respectively, and the amount of revenue recognized during the six nine months ended June September 30, 2026 and 2025 that was included in the Company's contract liabilities balance at the beginning of the period was $ 154,461 213,730 and $ 74,672 94,555 , respectively.
The following table includes estimated revenue expected to be recognized in the future related to remaining performance obligations as of June September 30, 2026:
1 unchanged paragraph
Transaction price allocated to remaining performance obligations $ 197,836 $ 152,588 $ 35,010 $ 9,321 $ 917
Transaction price allocated to remaining performance obligations $ 248,872 $ 197,292 $ 39,371 $ 10,395 $ 1,814
1 unchanged paragraph
Three months ended June 30, Six months ended June 30,
Three months ended September 30, Nine months ended September 30,
1 unchanged paragraph
Opening balance $ 30,773 $ 162,100 $ 38,230 $ 162,199 $ 34,556 $ 162,863 $ 41,348 $ 159,552
Amortization 3,243 17,352 5,611 18,909 7,348 34,723 11,969 38,283
Closing Opening balance 23,880 165,513 36,486 171,012 $ 23,880 $ 165,513 $ 36,486 $ 171,012 $ 34,556 $ 162,863 $ 41,348 $ 159,552
Closing balance 20,690 172,101 35,591 168,547 20,690 172,101 35,591 168,547
Amortization 3,344 17,349 6,580 22,428 10,692 52,072 18,549 60,711
GENPACT LIMITED AND ITS SUBSIDIARIES
Note 21: Interest income (expense), net 8 changes
Three months ended June 30, Six months ended June 30,
Interest income $ 4,748 $ 4,534 $ 14,901 $ 10,789
Interest expense ( 19,895 ) ( 18,019 ) $ ( 41,650 ) ( 35,720 )
Interest income (expense), net $ ( 15,147 ) $ ( 13,485 ) $ ( 26,749 ) $ ( 24,931 )
Three months ended September 30, Nine months ended September 30,
Interest income $ 3,526 $ 5,140 $ 18,427 $ 15,929
Interest expense ( 19,994 ) ( 17,925 ) $ ( 61,644 ) ( 53,645 )
Interest income (expense), net $ ( 16,468 ) $ ( 12,785 ) $ ( 43,217 ) $ ( 37,716 )
Note 22: Income taxes 1 change
1 unchanged paragraph
The Company's effective tax rate ("ETR") was 23.7 22.8 % for the three months ended June September 30, 2026, down from 24.9 23.0 % for the three months ended June September 30, 2025. The Company's ETR was 23.7 23.4 % for the six nine months ended June September 30, 2026, down from 25.1 24.4 % for the six nine months ended June September 30, 2025. The decrease in the Company's ETR in both periods was primarily driven by optimization of intercompany financing, as well as the geographic mix of the Company's pre-tax income. and the impacts of other discrete items.
Note 23: Commitments and contingencies 4 changes
As of June September 30, 2026 and December 31, 2025, the Company has committed to spend $ 9,538 18,902 and $ 16,542 , respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of these purchases.
The Company has outstanding bank guarantees and letters of credit amounting to $ 9,105 and $ 9,245 as of September 30, 2026 and December 31, 2025, respectively. Bank guarantees are generally provided to government agencies or for leases. These guarantees may be revoked if the beneficiary suffers any losses or damages through the breach of any of the covenants contained in the agreements governing such guarantees.
Certain units of the Company's Indian subsidiaries are established as Software Technology Parks of India units or Special Economic Zone ("SEZ") units under the relevant regulations issued by the Government of India. These units are exempt from customs and other duties on imported and indigenous capital goods, stores and spares. SEZ units are also exempt from the Indian Goods and Services Tax that was introduced in India in 2017. The Company has undertaken to pay taxes and duties, if any, in respect of capital goods, stores, spares and services consumed duty-free, in the event that certain terms and conditions are not fulfilled.
The Company is involved in various claims and legal proceedings arising in the ordinary course of business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. Based on the Company's assessment, including the availability of insurance recoveries, the Company's management does not believe that any current claims or legal proceedings (other than the specific matters described below, if decided adversely), individually or in aggregate, will have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows. This assessment is based on the Company's current understanding of relevant facts and circumstances. As such, the Company's view of these matters is subject to inherent uncertainties and may change in the future. The Company will continuously monitor these matters to assess potential impacts to the financial statements.
1 unchanged paragraph
Note 23: Commitments and contingencies (Continued) 5 changes
1 unchanged paragraph
and 5 more changes in the filing
Note 24: Subsequent events 1 change
and 1 more change in the filing
MD&A 1 change
and 1 more change in the filing
Forward-looking statements 238 changes
1 unchanged paragraph
13 unchanged paragraphs
4 unchanged paragraphs
15 unchanged paragraphs
1 unchanged paragraph
9 unchanged paragraphs
3 unchanged paragraphs
1 unchanged paragraph
2 unchanged paragraphs
2 unchanged paragraphs
5 unchanged paragraphs
3 unchanged paragraphs
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
2 unchanged paragraphs
1 unchanged paragraph
1 unchanged paragraph
3 unchanged paragraphs
1 unchanged paragraph
2 unchanged paragraphs
1 unchanged paragraph
2 unchanged paragraphs
1 unchanged paragraph
1 unchanged paragraph
2 unchanged paragraphs
2 unchanged paragraphs
2 unchanged paragraphs
2 unchanged paragraphs
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
2 unchanged paragraphs
4 unchanged paragraphs
2 unchanged paragraphs
4 unchanged paragraphs
1 unchanged paragraph
2 unchanged paragraphs
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
1 unchanged paragraph
4 unchanged paragraphs
and 238 more changes in the filing
Market risk 2 changes
3 unchanged paragraphs
1 unchanged paragraph
and 2 more changes in the filing
Controls and procedures 2 changes
4 unchanged paragraphs
and 2 more changes in the filing
Legal proceedings 1 change
and 1 more change in the filing
Risk factors 24 changes
and 24 more changes in the filing
Use of proceeds 9 changes
1 unchanged paragraph
4 unchanged paragraphs
1 unchanged paragraph
and 9 more changes in the filing
Other information 9 changes
1 unchanged paragraph
and 9 more changes in the filing
Exhibits 8 changes
2 unchanged paragraphs
14 unchanged paragraphs
2 unchanged paragraphs
1 unchanged paragraph
and 8 more changes in the filing
Unchanged: Note 2: Management's Discussion and Analysis of Financial Condition and Results of Operations, Note 3: Quantitative and Qualitative Disclosures About Market Risk, Note 4: Controls and Procedures, Notes to the financial statements, Note 2: Summary of significant accounting policies, Note 18: Segment reporting, Unregistered sales of stock
Only in this filing: Note 8: Property, plant and equipment, net (Continued), Note 16: Capital stock (Continued), Note 20: Other operating (income) expense, net
Compared by code from the two filings' text and XBRL. Not advice.
The reading, claim by claim
- Gross profit was $526,717 thousand, and operating income was $210,979 thousand.
- Genpact LTD's total assets were $5,639,212 thousand as of September 30, 2026.
- Total liabilities were $2,930,640 thousand, and shareholders' equity was $2,708,572 thousand.
- The company's common shares outstanding were 167,227,005 as of September 30, 2026.
- In its 10-Q for the quarter ended September 30, 2026, Genpact LTD reported a net income of $151.7 million.
5 of 5 claims matched the filing text.
From the filing's financial data, not stated in its text
From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026
- Revenue increased by 7.3% compared to the same period in the previous year.
- The company's revenue for the quarter was $1.4 billion, according to the filing.
- The company's gross margin was 38.0% for the quarter.
From the filing
Item 1. Unaudited Consolidated Financial Statements
Item 1. Unaudited Consolidated Financial Statements
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Balance Sheets
(Unaudited)
(In thousands, except per share data and share count)
Notes As of September 30, 2026 As of December 31, 2025
Assets
Current assets
Cash and cash equivalents $ 499,053 $ 853,836
Short-term investments — 350,000
Operating lease right-of-use assets 198,880 181,708
Liabilities and equity
Current liabilities
Shareholders' equity
Preferred shares, $ 0.01 par value, 250,000,000 authorized, none issued
— —
Accumulated other comprehensive income (loss) ( 966,327 ) ( 861,444 )
Total equity $ 2,708,5723 $ 2,549,401
Commitments and contingencies 23
Total liabilities and equity $ 5,639,212 $ 5,843,267
See accompanying notes to the Consolidated Financial Statements.
3
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Income
(Unaudited)
(In thousands, except per share data and share count)
Three months ended September 30, Nine months ended September 30,
Earnings per common share 17
Weighted average number of common shares used in computing earnings per common share 17
See accompanying notes to the Consolidated Financial Statements.
4
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Comprehensive Income (Loss)
(Unaudited)
(In thousands)
Three months ended September 30, Nine months ended September 30,
See accompanying notes to the Consolidated Financial Statements.
5
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Equity
For the three months ended September 30, 2026
(Unaudited)
(In thousands, except share count)
Common shares Accumulated Other
Comprehensive
Income (Loss)
No. of Shares Amount Additional
Paid-in Capital Retained
Earnings Total
Equity
Balance as of July 1, 2026 168,028,805 $ 1,673 $ 2,050,128 $ 1,500,595 $ ( 947,599 ) $ 2,604,797
Issuance of common shares on exercise of options (Note 15) — — — — — —
Dividend ($ 0.1875 per common share, Note 16)
See accompanying notes to the Consolidated Financial Statements.
6
GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Equity
For the nine months ended September 30, 2026
(Unaudited)
(In thousands, except share count)
Common shares Accumulated Other
Comprehensive
Income (Loss)
No. of Shares Amount Additional
Paid-in Capital Retained
Ear
Similar companies
Companies of similar size in SIC 8742 and related industry codes: the same peer list as the financial tables.
- Booz Allen Hamilton Holding BAH public float $11.5B, Sep 30, 2025
- Fti Consulting FCN public float $4.6B, Jun 30, 2025
- Exponent EXPO public float $3.0B, Jul 4, 2025
- Huron Consulting Group HURN public float $2.3B, Jun 30, 2025
- Premier PINC